Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46749 | 0.86 | SERPINE1 (0.41) | MAOBALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6000184 | 0.85 | LTA4H (0.40) | ALDH1A1KDM4EGAADHFRMAPT | |
| SCHEMBL39775 | 0.83 | CLK4 (0.53) | ALDH1A1KDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL2719825 | 0.82 | MAP4K4 (0.43) | ALDH1A1KDM4EGAAHTR1ACYP1A2 | |
| SCHEMBL19595872 | 0.79 | ALKBH5 (0.42) | ALDH1A1KDM4EGAAHTR1AKCNQ2 | |
| SCHEMBL46433 | 0.77 | ABL1 (0.49) | ALDH1A1KDM4EMAPT | |
| SCHEMBL46951 | 0.74 | SLC34A2 (0.49) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18482258 | 0.74 | KDM4E (0.41) | ALDH1A1KDM4EGAAHTR1AKCNQ2 | |
| SCHEMBL46775 | 0.74 | MAPK13 (0.42) | — | |
| SCHEMBL39728 | 0.74 | BRAF (0.46) | KDM4EGAACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | ALOX5AP 2602/4885FEN1 2368/4885MAOB 1943/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | ALOX5AP 2602/4885FEN1 2368/4885MAOB 1943/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | ALOX5AP 2504/4885FEN1 2767/4885MAOB 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.